Drug Trial Radar · NCT03652077
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Last checked: Nov 20, 2026Latest source record: Nov 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Sep 24, 2018
Primary completion
Aug 18, 2021
Study completion Aug 18, 2021
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Aug 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.
Conditions
- Cervical Cancer
- Gastric Cancer
- Stomach Cancer
- Gastroesophageal Junction Cancer
- Esophageal Cancer
- Hepatocellular Carcinoma
- Melanoma
- Uveal Melanoma
- Merkel Cell Carcinoma
- Mesothelioma
- MSI
- Non-small Cell Lung Cancer
- NSCLC
- Ovarian Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Small Cell Lung Cancer
- Renal Cell Carcinoma
- RCC
- Triple-negative Breast Cancer
- Urothelial Carcinoma
- Mismatch Repair Deficiency
Interventions
INCAGN02390Drug
Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation in 7 total cohorts to determine the maximum tolerated dose or PAD.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of treatment-emergent adverse eventsTime frame: Up to 12 months
- Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390 (Part 1 only)Time frame: Up to approximately 1 month
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
The Angeles Clinical and Research Institute
Los Angeles, California
University of Mississippi
Jackson, Mississippi
Hackensack Medical Center
Hackensack, New Jersey
Carolina BioOncology
Huntsville, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.